• OPEXA THERAPEUTICS ORD (OPXA)


    wer war da dabei :lol:

    Schachspieler können ausgezeichnet Varianten am Schachbrett berechnen. Für viele ist ein kleiner momentaner persönlicher Vorteil wichtiger als ein weit größerer Vorteil von morgen.

  • OPEXA

    Novartis schliesst Abkommen mit Opexa im Bereich Stammzellen

    07.08.2009 14:05


    Basel (awp) - Die Novartis AG hat mit der an der Nasdaq kotierten Opexa Therapeutics Inc. ein exklusives Abkommen geschlossen. Dabei geht es um die Weiterentwicklung von Opexas neuartiger Stammzellen-Therapie, wie Opexa am Freitag mitteilte. Opexa erhält dafür von Novartis eine Barzahlung von 3 Mio USD, zusätzlich 1 Mio USD über sechs Monate verteilt für den Technologietransfer sowie Meilensteinzahlungen. Insgesamt könnten die Zahlungen ohne Lizenzgebühren auf über 50 Mio USD zu stehen kommen.


    cf/uh

    Schachspieler können ausgezeichnet Varianten am Schachbrett berechnen. Für viele ist ein kleiner momentaner persönlicher Vorteil wichtiger als ein weit größerer Vorteil von morgen.

  • OPEXA

    Ich war dabei (einige Stunden lang).




    Gekauft bei 3.93 und verkauft bei 6.20


    http://www.marketwatch.com/investing/stock/opxa

    Wer nach vorne schauen will, muss erst mal zurück schauen:



    External Content www.youtube.com
    Content embedded from external sources will not be displayed without your consent.
    Through the activation of external content, you agree that personal data may be transferred to third party platforms. We have provided more information on this in our privacy policy.

  • OPEXA

    23-09-2009 16:23 UPDATE 1-Opexa gets first milestone payment from Novartis


    Name Letzter Veränderung

    NOVARTIS N 50.60 0.20 (0.40 *wacko*

    OPEXA THERAPEUTICS ORD 4.35 0.89 (25.72 *wacko*


    * Says gets $500,000 as technology transfer fee


    * Gets $850,000 from exercise of outstanding warrants


    * Shares rise 35 percent




    Sept 23 (Reuters) - Opexa Therapeutics Inc said it received $500,000 as a milestone payment from Swiss drugmaker Novartis under a stem cell technology transfer agreement, sending Opexa's shares up 35 percent.


    Also, the company said it received about $850,000 from the exercise of outstanding warrants at a strike price of $1.78.


    Last month, Novartis agreed to acquire Opexa's preclinical-stage stem cell technology, resolving the tiny biopharmaceutical company's near-term liquidity needs.


    Under the terms of the deal, Opexa received an upfront cash payment of $3 million and was entitled to an additional $1 million as a technology transfer fee to be paid over the course of a six-month period, the company said in a statement.


    The $500,000 milestone is part of this $1 million technology transfer fee, Opexa said.


    Shares of the company were up 25 percent at $4.34 in early-morning trade Wednesday, making them the biggest percentage gainer on Nasdaq.




    23-09-2009 16:29 STOCKS NEWS US-Opexa shares soar, gets first milestone payment


    Name Letzter Veränderung

    NOVARTIS N 50.65 0.25 (0.50 *wacko*

    OPEXA THERAPEUTICS ORD 4.34 0.88 (25.43 *wacko*


    Stocks on the move


    Real-time Equity news


    U.S. stock market report


    1009 ET 23Sept2009-Opexa shares soar, gets first milestone payment------------------------------------------------------------------------------


    Shares of Opexa Therapeutics Inc soared on Wednesday, after the company said it received $500,000 as a milestone payment from Swiss drugmaker Novartis under a stem cell technology transfer agreement.


    The company also said it received about $850,000 from the exercise of outstanding warrants at a strike price of $1.78.


    For details, see


    The stock advanced 25 percent to $4.33.


    Reuters Messaging: ryan.vlastelica.reuters.com@reuters.net


    0957 ET 23Sept2009-BMO downgrades REITs to 'market perform' ------------------------------------------------------------------------------


    BMO Capital Markets lowered its industry rating on U.S. Real Estate Investment Trusts (REITs) to 'market perform' from 'outperform' citing valuation.


    In a note to clients, the firm wrote that the recent run in stocks had created a condition of fair value for the REITs.


    As part of its call, the firm downgraded U-Store-It, AvalonBay Communities Inc and Corporate Office Properties Trust to 'market perform' from 'outperform.'


    For details, see


    Reuters Messaging: ryan.vlastelica.reuters.com@reuters.net


    0944 ET 23Sept2009-Plutonic, GE unit to buy Canada wind farm ------------------------------------------------------------------------------


    Plutonic Power Corp and a unit of General Electric Co said on Wednesday that they had committed to buying the Dokie Ridge wind project in western Canada after completing a due diligence investigation.


    GE Energy Financial Services and Plutonic, a small Canadian hydro-electric producer, announced on June 1 that they planned to buy the uncompleted 144-megawatt project, whose owner, EarthFirst Canada, filed for creditor protection last year.


    For details, see


    Shares of GE, a Dow component, rose 1.5 percent to $17.27 on Wednesday.


    Reuters Messaging: ryan.vlastelica.reuters.com@reuters.net


    0930 ET 23Sept2009-Markets edge up at open on General Mills ------------------------------------------------------------------------------


    U.S. markets opened modestly higher on Wednesday, ahead of a Federal Reserve policy statement and following results by General Mills Inc, which beat profit estimates.


    The Dow Jones industrial average rose 0.1 percent to 9,836.30 while the S&P 500 gained 0.1 percent to 1,072.96 and the Nasdaq was up 0.3 percent to 2,151.71.


    Reuters Messaging: ryan.vlastelica.reuters.com@reuters.net


    0913 ET 23Sept2009-M. Stanley upgrades CenturyTel to 'overweight' ------------------------------------------------------------------------------


    Morgan Stanley upgraded rural telephone provider CenturyTel Inc to 'overweight' from 'equal-weight,' citing its attractive valuation, ongoing merger synergies, and potential buybacks.


    'CenturyLink has announced a debt tender offer for up to $800 million of 2010-2013 notes, which will allow the company to effectively extend its maturities on favorable terms,' the firm added.

  • OPEXA

    Das Unternehmen verliert leider auch immer mehr an Intersse. Ich würd abwarten, bis NEWS kommen. Die abwärtsfahrt sieht zwar nicht steil aus, aber lang.


    Ansonsten ist die Aktie auch nur für einen kurzen Zock zu gebrauchen. Auch wenn sie jetzt eine neuen 3-Jahresvertrag mit Novartis hat.

    Wer nach vorne schauen will, muss erst mal zurück schauen:



    External Content www.youtube.com
    Content embedded from external sources will not be displayed without your consent.
    Through the activation of external content, you agree that personal data may be transferred to third party platforms. We have provided more information on this in our privacy policy.

  • OPEXA

    Ja ist wirklich so, wie ich sagte.


    Sieht als würde es morgen am Anfang wieder down gehen. Aber ich vermute stark, dass sich dass nach schon nach ein paar Stunden stabilisiert.

    Wer nach vorne schauen will, muss erst mal zurück schauen:



    External Content www.youtube.com
    Content embedded from external sources will not be displayed without your consent.
    Through the activation of external content, you agree that personal data may be transferred to third party platforms. We have provided more information on this in our privacy policy.

  • OPEXA

    Die Aktie hat diese Woche rund 30% zugenommen. Spekulationen über erfolgreiche Tests des Medikaments Tovaxin in der Phase 2b sind dafür der Grund. Die Ergebnisse werden am 14. April nach Börsenschluss bekannt gegeben.


    http://www.google.com/finance?q=NASDAQ:OPXA


    Opexa Therapeutics to present data from Phase 2b TERMS clinical trial for Tovaxin at 62nd AAN meeting

    7. April 2010 03:31


    Opexa Therapeutics, Inc. (NASDAQ: OPXA), a company developing a novel T-cell therapy for multiple sclerosis (MS), announced today that the Company has been selected to present key efficacy data at the upcoming American Academy of Neurology (AAN) 62nd Annual Meeting to be held in Toronto, Canada.


    Dawn McGuire, M.D., Chair of Opexa's Clinical Advisory Board and the Company's acting Chief Medical Officer, will present data from the Phase 2b TERMS clinical trial which demonstrated promising efficacy and safety data in patients treated with Tovaxin®, the Company's lead therapy for MS.


    The data will be presented during a poster session on Wednesday, April 14, 2010 from 6:00 to 7:30 p.m. at Poster Session P04, located at P04.211 in the poster hall under the following title: Safety and Efficacy of Autologous T-Cell Immunotherapy (Tovaxin) in Patients with Active Relapsing-Remitting Multiple Sclerosis.


    Established in 1948, the American Academy of Neurology is an international professional association of more than 22,000 neurologists and neuroscience professionals. The 62nd Annual Meeting will be held in Toronto, April 10 to April 17, 2010, and will highlight the latest in neurologic research through key lectures, over 2,300 poster and platform sessions, and 175 educational programs. More than 10,000 people are expected to attend the meeting this year.


    SOURCE Opexa Therapeutics, Inc.

    Wer nach vorne schauen will, muss erst mal zurück schauen:



    External Content www.youtube.com
    Content embedded from external sources will not be displayed without your consent.
    Through the activation of external content, you agree that personal data may be transferred to third party platforms. We have provided more information on this in our privacy policy.

  • OPEXA

    Dakytrader wrote:

    Quote

    Quote:


    Deinen Gedankensprung würde ich gerne wissen?


    Rein subjektiv. Sorry, war kein allzu schlauer Beitrag von mir. So kurz vor der Bekanntgabe der Tovaxin Testresultate hätte ich einfach keinen so starken Rückgang erwartet. Da ich im Moment sehr kurzfristig trade, bin ich mit einem blauen Auge noch rausgesprungen um den Einsatz auf einen anderen interessanten Titel zu setzen. Dienstag oder Mittwoch siehts wieder anders aus mit Opexa und ich würde sicher noch ohne blaues Auge und einem Grinsen im Gesicht rauskommen.


    Greez Hotzenplotz